PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies

被引:2
|
作者
Cohen, Dan [1 ]
Hazut Krauthammer, Shir [1 ]
Fahoum, Ibrahim [2 ]
Kesler, Mikhail [1 ]
Even-Sapir, Einat [1 ,3 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Nucl Med, 6 Weizmann St, IL-6423906 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Inst Pathol, Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
PET-CT; 18F-FDG; PSMA antigen; Somatostatin; Prostate cancer; SMALL-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; GA-68-DOTA-TYR(3)-OCTREOTIDE PET; PROGNOSTIC-SIGNIFICANCE; HISTOLOGICAL VARIANTS; CLINICAL UTILITY; F-18-FDG PET/CT; NORMAL PATTERNS; FDG-PET; CANCER;
D O I
10.1007/s00330-023-09619-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naive prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [F-18]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with Ga-68 and prostate-specific membrane antigen (PSMA)-ligands labeled with either F-18 or Ga-68, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [F-18]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [F-18]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [F-18]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended.
引用
收藏
页码:6502 / 6512
页数:11
相关论文
共 50 条
  • [1] PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies
    Dan Cohen
    Shir Hazut Krauthammer
    Ibrahim Fahoum
    Mikhail Kesler
    Einat Even-Sapir
    European Radiology, 2023, 33 : 6502 - 6512
  • [2] A WHOLE-BODY IMAGING TECHNIQUE FOR PET
    GUERRERO, TM
    HOFFMAN, EJ
    DAHLBOM, M
    HAWKINS, R
    PHELPS, ME
    JOURNAL OF NUCLEAR MEDICINE, 1989, 30 (10) : 1750 - 1750
  • [3] Whole-body imaging with PET/MRI
    Gaa, J
    Rummeny, EJ
    Seemann, MD
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2004, 9 (06) : 309 - 312
  • [4] Whole-body FDG PET and CT imaging of malignancies using a combined PET CT scanner.
    Charron, M
    Beyer, T
    Kinahan, PE
    Meltzer, CC
    Dachille, MA
    Townsend, DW
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 256P - 256P
  • [5] CHARACTERIZATION OF A WHOLE-BODY IMAGING TECHNIQUE FOR PET
    GUERRERO, TM
    HOFFMAN, EJ
    DAHLBOM, M
    CUTLER, PD
    HAWKINS, RA
    PHELPS, ME
    IEEE TRANSACTIONS ON NUCLEAR SCIENCE, 1990, 37 (02) : 676 - 680
  • [6] Frontiers in Neuroscience Imaging: Whole-Body PET
    Thaker, Ashesh A.
    Chien, Austin L.
    Dubroff, Jacob G.
    PET CLINICS, 2021, 16 (01) : 137 - 146
  • [7] New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
    Fortunati, Emilia
    Argalia, Giulia
    Zanoni, Lucia
    Fanti, Stefano
    Ambrosini, Valentina
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (05) : 703 - 720
  • [8] New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
    Emilia Fortunati
    Giulia Argalia
    Lucia Zanoni
    Stefano Fanti
    Valentina Ambrosini
    Current Treatment Options in Oncology, 2022, 23 : 703 - 720
  • [9] Imaging inmultiplemyeloma. Skeletal survey, whole-body CT, whole-body MRI or PET?
    Mosebach, Jennifer
    Beuthien-Baumann, Bettina
    Schlemmer, Heinz-Peter
    Delorme, Stefan
    ONKOLOGE, 2018, 24 (08): : 584 - 595
  • [10] Whole-body PET/MRI: The future in oncological imaging
    Seemann, MD
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2005, 4 (05) : 577 - 582